David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses that we are now getting a longer-term follow-up in key CAR-T trials for Lymphoma. Namely, the JULIET (NCT02445248) and ZUMA-1 (NCT02348216) trial. Prof. Maloney mentions ongoing trials working to treat patients at an earlier disease state and in other histologies. Lisocabtagene maraleucel is being targeted in chronic lymphocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2018, held in Amsterdam, Netherlands.